|Podcasts|July 22, 2021

Episode 87: Attacking Bladder Cancer From All Sides

Arthur Kuan, CEO of CG Oncology, talks about the present and future of bladder cancer therapies, and how he’s committed to making a difference.

Arthur Kuan, CEO of CG Oncology, discusses bladder cancer therapies and how his company is contributing to the fight.


Related to this article

Pharmaceutical Executive Daily
FDA reportedly shelves its Commissioner’s National Priority Voucher program, Eli Lilly breaks ground on a $3.5 billion Pennsylvania manufacturing site for next-generation obesity treatments, and Parexel’s Stacy Hurt on how small protocol decisions can become enrollment and retention barriers.
Pharmaceutical Executive Daily
FDA approves Merck KGaA’s Pimjetmi for tenosynovial giant cell tumor, Parexel’s Stacy Hurt on when patient input should enter the clinical research process, and Ignite Proteomics’ Dr. Brian Corgiat on adjusting for tumor mutations in treatment decisions.